Bluebird bio (BLUE) and Vertex (VRTX) have entered into outcome-based agreements with CMS aimed at expanding patient access ...

IGM Biosciences has pivoted from cancer therapeutics to autoimmune diseases despite setbacks, showing a 25% stock increase since last October. Click for more on IGMS.